Alto Neuroscience Q2 net loss $27.6M; expands ALTO-207 with Phase 3 monotherapy trial

Alto Neuroscience, Inc.

Net loss $27.6M in Q2 2026 vs $17.7M year-ago; R&D expenses $22.1M vs $13.1M.
July 2026 offering raised ~$100M gross; pro forma cash ~$338M, runway through 2030.
ALTO-207 Phase 3 monotherapy TRD trial added; PACE-2 Phase 3 adjunctive to start early 2027; PACE-1 Phase 2b topline 2H 2027.
Nature Medicine PRIME-PRAXOL: pramipexole reduced anhedonia (SHAPS p=0.006, Hedges' g=0.62) in MDD/bipolar depression.
ALTO-300 Phase 2b MDD topline 1H 2027; ALTO-100 Phase 2b BPD topline mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.